ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms Supplementary table 1

The ENABLE study is supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) 5×1000 call ‘Metastatic disease: the key unmet need in oncology’ to MYNERVA (MYeloid NEoplasms Research Venture AIRC), project #21267; Cancer Research UK [C355/A26819] and FC AECC and AIRC under the Accelerator Award Program. The drug venetoclax is provided free of cost from AbbVie, while decitabine is used according to approved reimbursement criteria in Italy. A Vannucchi was involved in advisory boards of AbbVie. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.